SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $23,510 | -25.3% | 500,000 | -33.3% | 0.73% | -61.0% |
| Q1 2023 | $31,470 | +10.0% | 750,000 | 0.0% | 1.87% | +17.1% |
| Q4 2022 | $28,605 | -99.9% | 750,000 | 0.0% | 1.60% | +27.5% |
| Q3 2022 | $29,370,000 | +102.1% | 750,000 | +66.7% | 1.25% | +61.5% |
| Q2 2022 | $14,535,000 | -56.1% | 450,000 | -55.0% | 0.78% | -44.0% |
| Q1 2022 | $33,100,000 | -37.8% | 1,000,000 | -20.0% | 1.38% | -4.0% |
| Q4 2021 | $53,175,000 | +20.0% | 1,250,000 | +25.0% | 1.44% | +45.6% |
| Q3 2021 | $44,310,000 | -22.0% | 1,000,000 | 0.0% | 0.99% | -14.1% |
| Q2 2021 | $56,810,000 | +16.8% | 1,000,000 | +53.8% | 1.15% | +34.1% |
| Q1 2021 | $48,653,000 | +40.6% | 650,000 | +62.5% | 0.86% | +15.7% |
| Q4 2020 | $34,604,000 | +154.7% | 400,000 | +79.9% | 0.74% | +125.2% |
| Q3 2020 | $13,587,000 | +39.6% | 222,300 | -5.0% | 0.33% | +21.3% |
| Q2 2020 | $9,730,000 | -3.2% | 234,000 | -33.1% | 0.27% | -36.0% |
| Q1 2020 | $10,052,000 | -7.2% | 350,000 | +133.3% | 0.42% | +1.7% |
| Q4 2019 | $10,829,000 | -48.5% | 150,000 | 0.0% | 0.42% | -50.5% |
| Q3 2019 | $21,044,000 | -23.4% | 150,000 | 0.0% | 0.84% | -24.0% |
| Q2 2019 | $27,464,000 | +38.1% | 150,000 | +20.0% | 1.11% | +36.8% |
| Q1 2019 | $19,881,000 | +107.5% | 125,000 | +25.0% | 0.81% | +128.7% |
| Q4 2018 | $9,579,000 | -32.2% | 100,000 | 0.0% | 0.36% | -3.3% |
| Q3 2018 | $14,125,000 | -9.8% | 100,000 | 0.0% | 0.37% | +10.2% |
| Q2 2018 | $15,653,000 | -2.8% | 100,000 | 0.0% | 0.33% | +64.9% |
| Q1 2018 | $16,107,000 | +30.4% | 100,000 | +33.3% | 0.20% | +8.6% |
| Q4 2017 | $12,353,000 | +32.2% | 75,000 | -50.0% | 0.19% | +15.5% |
| Q3 2017 | $9,345,000 | +30.4% | 150,000 | +66.7% | 0.16% | +28.8% |
| Q2 2017 | $7,168,000 | -42.4% | 90,000 | -48.6% | 0.12% | -54.7% |
| Q1 2017 | $12,437,000 | +62.4% | 175,000 | +16.7% | 0.28% | +62.4% |
| Q4 2016 | $7,659,000 | -16.8% | 150,000 | -25.0% | 0.17% | -6.6% |
| Q3 2016 | $9,210,000 | +205.7% | 200,000 | +100.0% | 0.18% | +193.5% |
| Q2 2016 | $3,013,000 | – | 100,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
| Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
| Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
| DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
| Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
| Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
| Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
| Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
| Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
| SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |